BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26810065)

  • 21. Over-expression of metallothionein predicts chemoresistance in breast cancer.
    Yap X; Tan HY; Huang J; Lai Y; Yip GW; Tan PH; Bay BH
    J Pathol; 2009 Mar; 217(4):563-70. PubMed ID: 19116991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression.
    Huang Y; Jiang D; Sui M; Wang X; Fan W
    Oncol Rep; 2017 Feb; 37(2):705-712. PubMed ID: 28000875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.
    Shen H; Wang D; Li L; Yang S; Chen X; Zhou S; Zhong S; Zhao J; Tang J
    Gene; 2017 Jan; 596():110-118. PubMed ID: 27746366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Silence of long noncoding RNA UCA1 inhibits malignant proliferation and chemotherapy resistance to adriamycin in gastric cancer.
    Shang C; Guo Y; Zhang J; Huang B
    Cancer Chemother Pharmacol; 2016 May; 77(5):1061-7. PubMed ID: 27056384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High expression of TRIM44 is associated with enhanced cell proliferation, migration, invasion, and resistance to doxorubicin in hepatocellular carcinoma.
    Zhu X; Wu Y; Miao X; Li C; Yin H; Yang S; Lu X; Liu Y; Chen Y; Shen R; Chen X; He S
    Tumour Biol; 2016 Nov; 37(11):14615-14628. PubMed ID: 27619678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
    Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY
    Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects.
    Rincón R; Cristóbal I; Zazo S; Arpí O; Menéndez S; Manso R; Lluch A; Eroles P; Rovira A; Albanell J; García-Foncillas J; Madoz-Gúrpide J; Rojo F
    Oncotarget; 2015 Feb; 6(6):4299-314. PubMed ID: 25726524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transmembrane TNF-alpha promotes chemoresistance in breast cancer cells.
    Zhang Z; Lin G; Yan Y; Li X; Hu Y; Wang J; Yin B; Wu Y; Li Z; Yang XP
    Oncogene; 2018 Jun; 37(25):3456-3470. PubMed ID: 29559745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase.
    Bartholomeusz C; Gonzalez-Angulo AM; Kazansky A; Krishnamurthy S; Liu P; Yuan LX; Yamasaki F; Liu S; Hayashi N; Zhang D; Esteva FJ; Hortobagyi GN; Ueno NT
    Clin Cancer Res; 2010 Mar; 16(6):1802-11. PubMed ID: 20215547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1.
    Ming J; Ruan S; Wang M; Ye D; Fan N; Meng Q; Tian B; Huang T
    Oncotarget; 2015 Dec; 6(38):40692-703. PubMed ID: 26517687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen-responsive finger protein as a new potential biomarker for breast cancer.
    Suzuki T; Urano T; Tsukui T; Horie-Inoue K; Moriya T; Ishida T; Muramatsu M; Ouchi Y; Sasano H; Inoue S
    Clin Cancer Res; 2005 Sep; 11(17):6148-54. PubMed ID: 16144914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin.
    Chekhun VF; Lukyanova NY; Burlaka CA; Bezdenezhnykh NA; Shpyleva SI; Tryndyak VP; Beland FA; Pogribny IP
    Int J Oncol; 2013 Nov; 43(5):1481-6. PubMed ID: 23969999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High Expression of SIRT1 Associates with the Doxorubicin Resistance of Breast Cancer through the Activation of Akt.
    Jin X; Wei Y; Liu Y; Chen Y; Zhao B; Huang J; Yu H; Li C
    Anticancer Agents Med Chem; 2020; 20(1):94-102. PubMed ID: 31746308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The oncogene LRF is a survival factor in chondrosarcoma and contributes to tumor malignancy and drug resistance.
    Kumari R; Li H; Haudenschild DR; Fierro F; Carlson CS; Overn P; Gupta L; Gupta K; Nolta J; Yik JH; Di Cesare PE
    Carcinogenesis; 2012 Nov; 33(11):2076-83. PubMed ID: 22847180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated nuclear S100P expression is associated with poor survival in early breast cancer patients.
    Maciejczyk A; Łacko A; Ekiert M; Jagoda E; Wysocka T; Matkowski R; Hałoń A; Györffy B; Lage H; Surowiak P
    Histol Histopathol; 2013 Apr; 28(4):513-24. PubMed ID: 23364898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy.
    Bisaro B; Sciortino M; Colombo S; Camacho Leal MP; Costamagna A; Castellano I; Montemurro F; Rossi V; Valabrega G; Turco E; Defilippi P; Cabodi S
    Oncotarget; 2016 Jan; 7(4):4442-53. PubMed ID: 26716506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High TXNDC5 expression predicts poor prognosis in renal cell carcinoma.
    Mo R; Peng J; Xiao J; Ma J; Li W; Wang J; Ruan Y; Ma S; Hong Y; Wang C; Gao K; Fan J
    Tumour Biol; 2016 Jul; 37(7):9797-806. PubMed ID: 26810069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance.
    Liu J; Wei T; Zhao J; Huang Y; Deng H; Kumar A; Wang C; Liang Z; Ma X; Liang XJ
    Biomaterials; 2016 Jun; 91():44-56. PubMed ID: 26994877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.
    Luhtala S; Staff S; Tanner M; Isola J
    Tumour Biol; 2016 Jul; 37(7):9813-23. PubMed ID: 26810187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interactions between FGFR2 and RSK2-implications for breast cancer prognosis.
    Czaplinska D; Mieczkowski K; Supernat A; Skladanowski AC; Kordek R; Biernat W; Zaczek AJ; Romanska HM; Sadej R
    Tumour Biol; 2016 Oct; 37(10):13721-13731. PubMed ID: 27476168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.